References
- Haskell C M, Rosen L. Antineoplastic agents. Cancer Treatment. 5th ed, C M Haskell. W.B. Saunders Inc., Philadelphia 2001; 104–214
- Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334: 494–500
- Honkaniemi J, Kähärä V, Dastidar P, Latvala M, Hietaharju A, Salonen T, et al. Reversible posterior leukoencephalopathy after combination chemotherapy. Neuroradiology 2000; 42: 895–899
- King P D, Perry M C. Hepatotoxicity of chemotherapy. The Oncologist 2001; 6: 162–176
- Dillon W P, Rowley H. The reversible posterior cerebral edema syndrome. Am J Neuroradiol 1998; 19: 591
- Tam C S, Galanos J, Seymour J F, Pitman A G, Stark R J, Prince H M. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol 2004; 77: 72–76
- Ay H, Buonanno F S, Schaefer P W, Le D A, Wang B, Gonzales R G, Koroshetz W J. Posterior leukoencephalopathy without severe hypertension utility of diffusion-weighted MRI. Neurology 1998; 51: 1369–1376
- Pas T D, Curigliano G, Catania C, Comandone A, Braud F D. Ifosfamide in the elderly: clinical considerations for a better drug management. Oncol Hematol 2000; 33: 129–135
- Carlson L, Goren M P, Bush D A, Griener J C, Quigley R, Tkaczewski I, et al. Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilm's tumor. Cancer Chem Pharm 1998; 41: 140–146
- Shin R K, Stern J W, Janss A J, Hunter J V, Liu G T. Reversible posterior leukoencephalopathy during the treatment of acute lymphoblastic leukemia. Neurology 2001; 56: 388–391